DexCom Inc. (NASDAQ:DXCM) dropped 0.3% during mid-day trading on Friday . The stock traded as low as $77.29 and last traded at $78.00, with a volume of 488,341 shares. The stock had previously closed at $78.21.

DXCM has been the subject of several analyst reports. BTIG Research initiated coverage on shares of DexCom in a report on Thursday, April 14th. They issued a “buy” rating and a $80.00 target price for the company. JPMorgan Chase & Co. restated a “buy” rating on shares of DexCom in a report on Monday, June 20th. Wedbush reiterated an “outperform” rating and set a $112.00 price objective on shares of DexCom in a report on Wednesday, June 15th. Robert W. Baird reiterated a “hold” rating on shares of DexCom in a report on Monday, May 16th. Finally, Zacks Investment Research lowered shares of DexCom from a “hold” rating to a “sell” rating in a report on Tuesday, June 28th. One analyst has rated the stock with a sell rating, two have issued a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $94.09.

The stock’s market cap is $6.58 billion. The stock has a 50-day moving average price of $72.45 and a 200 day moving average price of $68.63.

DexCom (NASDAQ:DXCM) last posted its earnings results on Wednesday, April 27th. The medical device company reported ($0.23) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.20) by $0.03. The business had revenue of $116.20 million for the quarter, compared to the consensus estimate of $110.37 million. During the same quarter in the prior year, the firm earned ($0.17) earnings per share. DexCom’s revenue was up 59.6% compared to the same quarter last year. On average, analysts forecast that DexCom Inc. will post ($0.37) earnings per share for the current year.

In other DexCom news, EVP Andrew K. Balo sold 5,000 shares of the company’s stock in a transaction dated Wednesday, June 29th. The shares were sold at an average price of $78.10, for a total value of $390,500.00. Following the transaction, the executive vice president now owns 134,979 shares of the company’s stock, valued at $10,541,859.90. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, SVP Jeffrey Moy sold 4,557 shares of the company’s stock in a transaction dated Wednesday, June 29th. The shares were sold at an average price of $80.00, for a total transaction of $364,560.00. Following the completion of the transaction, the senior vice president now directly owns 76,333 shares in the company, valued at approximately $6,106,640. The disclosure for this sale can be found here.

Several hedge funds have modified their holdings of the company. Principal Financial Group Inc. boosted its stake in shares of DexCom by 13.2% in the fourth quarter. Principal Financial Group Inc. now owns 79,782 shares of the medical device company’s stock valued at $6,534,000 after buying an additional 9,277 shares in the last quarter. Morgan Stanley boosted its stake in shares of DexCom by 0.6% in the fourth quarter. Morgan Stanley now owns 1,268,992 shares of the medical device company’s stock valued at $103,930,000 after buying an additional 7,662 shares in the last quarter. Vanguard Group Inc. boosted its stake in shares of DexCom by 3.7% in the fourth quarter. Vanguard Group Inc. now owns 5,241,624 shares of the medical device company’s stock valued at $429,289,000 after buying an additional 184,708 shares in the last quarter. IronBridge Capital Management LP boosted its stake in shares of DexCom by 5.4% in the fourth quarter. IronBridge Capital Management LP now owns 220,473 shares of the medical device company’s stock valued at $18,057,000 after buying an additional 11,340 shares in the last quarter. Finally, Artemis Investment Management LLP boosted its stake in shares of DexCom by 90.9% in the fourth quarter. Artemis Investment Management LLP now owns 19,792 shares of the medical device company’s stock valued at $1,620,000 after buying an additional 9,424 shares in the last quarter.

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers for the treatment of people with and without diabetes. Its products include SEVEN PLUS, DexCom G4, DexCom G4 PLATINUM, DexCom Share System and DexCom G5 Mobile.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.